Posted by Michael Wonder on 28 Jul 2026
Novartis receives Health Canada approval for Rhapsido (remibrutinib tablets) oral treatment for adults with CSU
27 July 2026 - Novartis Canada is proud to announce that Health Canada has issued a notice of compliance for Rhapsido (remibrutinib tablets) for the treatment of chronic spontaneous urticaria in adult patients who remain symptomatic despite H1 anti-histamine treatment.
The decision is supported by the Phase 3 REMIX-1 and REMIX-2 double-blind, randomized, placebo-controlled studies.
